NYC Health + Hospitals/Woodhull Receives IPRO Quality Award for Eliminating Central Line-Associated Bloodstream Infections

June 21, 2024
The hospital reduced the use of urinary catheters and central line catheters, which helped it achieve six consecutive quarters without central line-associated bloodstream infections.

NYC Health + Hospitals/Woodhull has received a 2024 IPRO Quality Award for “reducing the use of urinary catheters and central line catheters and achieving six consecutive quarters free of central line-associated bloodstream infections (CLABSIs).” Their website has the news.

Clinical teams from the inpatient medical, surgical, and critical care units were all involved in this endeavor. Each team would daily assess “each case where a central line or urinary catheter was in use and whether an alternative could be used instead, contributing to the prompt removal of these invasive devices as soon as they were no longer clinically required.” These efforts led to “decreased use of central line and urinary catheters, which in turn resulted in an overall reduction of central line-associated infections.”

The IPRO Hospital Quality Improvement Contract (HQIC) is “a federal program focused on improving the quality of care provided to Medicare patients across the United States and funded by the Centers for Medicare & Medicaid (CMS).”

Gregory Calliste, the CEO of NYC Health + Hospitals/Woodhull, recognizes the achievement as “a testament to the hard work and dedication of [the] staff in implementing effective infection prevention measures.”

About the Author

Matt MacKenzie | Associate Editor

Matt is Associate Editor for Healthcare Purchasing News.